We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Eurofins Launches New Tests and Massive Capacity for Detecting and Monitoring New Variants of SARS-CoV-2

By HospiMedica International staff writers
Posted on 18 Jan 2021
Print article
Illustration
Illustration
Eurofins (Luxembourg) has launched various initiatives to support the health authorities’ programs for the detection and monitoring of increasingly diverse SARS-CoV-2 variants.

The potential higher infectivity of some new viral strains underlines the need to identify, trace and track mutations across the complete viral genome. Through Eurofins’ current COVID-19 testing and clinical diagnostics activities globally and its partnerships with leading pharmaceutical and vaccine companies, the Group is able to closely monitor the identification of new variants of SARS-CoV-2.

Eurofins is increasing the capacity for its ARTIC Next Generation Sequencing (NGS) to more than 5,000 full genomes per day. The company has also launched NovaType, a SARS-CoV-2 RT-PCR assay, clinically validated for the identification of the B.1.1.7 variant, first identified in the UK, and the B.1.351 variant, first identified in South Africa. The test has a short turn-around time, making it ideal for retesting millions of positive samples to detect if the virus is the B.1.1.7 or B.1.351 variant. NovaType is already available as a Laboratory Developed Test (LDT) in Germany and will shortly be made available to the more than 50 Eurofins laboratories worldwide testing patients for COVID-19.

NovaType is being made available to health authorities in a number of European countries for trial and potential inclusion in their monitoring programs in response to these new variants. The NovaType assay will also be launched as a Research Use Only (RUO) kit in Europe by the end of January 2021. Eurofins intends to add new detection capabilities to NovaType as additional variants appear. Additionally, the Eurofins-Viracor SARS-CoV-2 RT-PCR diagnostic test maintains very high sensitivity in the detection of variants such as B.1.1.7 and B.1.351.

Related Links:
Eurofins 

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Examination Table
Powerline Backrest Top

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.